Generic Miacalcin Availability

Miacalcin is a brand name of calcitonin, approved by the FDA in the following formulation(s):

MIACALCIN (calcitonin salmon - injectable;injection)

  • Manufacturer: NOVARTIS
    Approval date: March 29, 1991
    Strength(s): 200 IU/ML [RLD]

MIACALCIN (calcitonin salmon - spray, metered;nasal)

  • Manufacturer: NOVARTIS
    Approval date: August 17, 1995
    Strength(s): 200 IU/SPRAY [RLD] [AB]

Has a generic version of Miacalcin been approved?

A generic version of Miacalcin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Miacalcin and have been approved by the FDA:

CALCITONIN-SALMON (calcitonin salmon spray, metered;nasal)

  • Manufacturer: APOTEX INC
    Approval date: November 17, 2008
    Strength(s): 200 IU/SPRAY [AB]
  • Manufacturer: PAR PHARM
    Approval date: June 8, 2009
    Strength(s): 200 IU/SPRAY [AB]

Note: No generic formulation of the following product is available.

  • calcitonin salmon - injectable;injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Miacalcin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Galenic compositions comprising calcitonin and their use
    Patent 5,733,569
    Issued: March 31, 1998
    Inventor(s): Azria; Moise & Cavanak; Thomas
    Assignee(s): Novartis Corporation
    Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.
    Patent expiration dates:
    • March 31, 2015
      ✓ 
      Patent use: NASAL ADMINISTRATION
  • Galenic compositions comprising calcitonin and their use
    Patent 5,759,565
    Issued: June 2, 1998
    Inventor(s): Azria; Moise & Cavanak; Thomas
    Assignee(s): Novartis Corporation
    Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.
    Patent expiration dates:
    • March 31, 2015

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web5)